Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer

Le Magnen, Clémentine; Bubendorf, Lukas; Rentsch, Cyrill A.; Mengus, Chantal; Gsponer, Joel; Zellweger, Tobias; Rieken, Malte; Thalmann, George N.; Cecchini, Marco G.; Germann, Markus; Bachmann, Alexander; Wyler, Stephen; Heberer, Michael; Spagnoli, Giulio C. (2013). Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer. Clinical cancer research, 19(19), pp. 5361-5371. American Association for Cancer Research 10.1158/1078-0432.CCR-12-2857

[img] Text
Thalmann_Clin Cancer Res_2013_19_5361.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

PURPOSE High aldehyde dehydrogenase (ALDH) has been suggested to selectively mark cells with high tumorigenic potential in established prostate cancer cell lines. However, the existence of cells with high ALDH activity (ALDH(bright)) in primary prostate cancer specimens has not been shown so far. We investigated the presence, phenotype, and clinical significance of ALDH(bright) populations in clinical prostate cancer specimens. EXPERIMENTAL DESIGN We used ALDEFLUOR technology and fluorescence-activated cell-sorting (FACS) staining to identify and characterize ALDH(bright) populations in cells freshly isolated from clinical prostate cancer specimens. Expression of genes encoding ALDH-specific isoforms was evaluated by quantitative real-time PCR in normal prostate, benign prostatic hyperplasia (BPH), and prostate cancer tissues. ALDH1A1-specific expression and prognostic significance were assessed by staining two tissue microarrays that included more than 500 samples of BPH, prostatic intraepithelial neoplasia (PIN), and multistage prostate cancer. RESULTS ALDH(bright) cells were detectable in freshly excised prostate cancer specimens (n = 39) and were mainly included within the EpCAM((+)) and Trop2((+)) cell populations. Although several ALDH isoforms were expressed to high extents in prostate cancer, only ALDH1A1 gene expression significantly correlated with ALDH activity (P < 0.01) and was increased in cancers with high Gleason scores (P = 0.03). Most importantly, ALDH1A1 protein was expressed significantly more frequently and at higher levels in advanced-stage than in low-stage prostate cancer and BPH. Notably, ALDH1A1 positivity was associated with poor survival (P = 0.02) in hormone-naïve patients. CONCLUSIONS Our data indicate that ALDH contributes to the identification of subsets of prostate cancer cells of potentially high clinical relevance.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Thalmann, George; Cecchini, Marco Giovanni and Germann, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

04 Jun 2014 09:19

Last Modified:

11 Jul 2018 17:15

Publisher DOI:

10.1158/1078-0432.CCR-12-2857

PubMed ID:

23969936

BORIS DOI:

10.7892/boris.43750

URI:

https://boris.unibe.ch/id/eprint/43750

Actions (login required)

Edit item Edit item
Provide Feedback